Skip to content

Kymera Therapeutics KYMR Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin-697.7%+193pp-891.1%-131pp-759.7%-62.2pp-697.5%-225pp-472.5%+83.3pp
Net margin-612%+182pp-794.1%-119pp-674.8%-58.8pp-616%-207pp-409.1%+66.5pp
Returns
Return on equity-27.1%-1.3pp-25.8%+6.3pp-32.1%+1.2pp-33.3%-1.1pp-32.2%+4.2pp
Return on invested capital-31.8%+1.3pp-33.1%+4.0pp-37.1%+6.5pp-43.6%-6.3pp-37.3%+7.2pp
Efficiency
Asset turnover0.0×0.0×0.0×0.0×0.1×0.0×
Liquidity
Current ratio10.8×+0.3×10.5×+3.1×7.4×-0.9×8.3×-0.2×8.5×+1.0×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$15.79-15.6%$18.70+72.5%$10.84-10.2%$12.08+23.1%$9.81-11.9%
Valuation
Market capitalization$6.8B+9.2%$6.22B+53.8%$4.05B+31.8%$3.07B+72.7%$1.78B-31.8%
Price / sales132.1×-26.7×158.8×+66.2×92.5×+23.9×68.7×+38.5×30.2×-25.2×
Price / book4.4×+0.5×3.9×-0.3×4.3×+1.1×3.2×+0.9×2.3×-0.9×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Kymera Therapeutics's ratios come from?
Every ratio is computed from Kymera Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.